<DOC>
	<DOCNO>NCT00109070</DOCNO>
	<brief_summary>This multicenter , Phase III , randomize , active-controlled trial evaluate efficacy safety rhuMAb VEGF ( Avastin ) add standard first-line chemotherapy use treat metastatic colorectal cancer . This trial enroll approximately 900 subject histologically confirm , previously untreated , bi-dimensionally measurable metastatic colorectal cancer .</brief_summary>
	<brief_title>A Study Evaluate Avastin Combination With Standard Chemotherapy Treat Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Written inform consent Age &gt; =18 year Histologically confirm colorectal carcinoma evidence metastasis ( i.e. , radiographic image biopsy ) Ability tolerate CT contrast dye Bidimensionally measurable disease ( minimum two lesion ) ECOG performance status 0 1 Use effective mean contraception woman childbearing potential Life expectancy &gt; 3 month Willingness capability accessible followup death study termination Genentech Prior chemotherapy adjuvant fluoropyrimidines combination leucovorin and/or levamisole Administration adjuvant fluoropyrimidines combination leucovorin and/or levamisole complete &lt; =12 month prior Day 0 Administration fluoropyrimidines radiosensitizer pelvic radiotherapy rectal cancer complete &lt; =12 month prior Day 0 Prior radiotherapy measurable , metastatic lesion ( ) use measure response Radiation therapy within 14 day prior Day 0 Prior biotherapy colorectal cancer Evidence clinically detectable ascites Day 0 Other invasive malignancy within 5 year prior Day 0 ( basal cell carcinoma skin ) History evidence upon physical examination CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke ) Active infection require parenteral antibiotic Day 0 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; fine needle aspiration within 7 day prior Day 0 Current recent ( within 10 day prior Day 0 ) use fulldose oral parenteral anticoagulant ( except require maintain patency preexisting , permanent indwell IV catheter ) thrombolytic agent ( subject receive warfarin , international normalize ratio [ INR ] &lt; 1.5 ; appropriate use heparin discuss Medical Monitor ) Chronic , daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication ( kind know inhibit platelet function dos use treat chronic inflammatory disease ) Pregnancy ( positive pregnancy test ) lactation Proteinuria baseline clinically significant impairment renal function Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Current recent ( within 28 day prior Day 0 ) participation another experimental drug study Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 1 year prior Day 0 Screening clinical laboratory value : *ANC &lt; 1500/uL ; *Platelet count &lt; 75,000/uL ; *INR &gt; =1.5 ; *Total bilirubin &gt; 1.6 mg/dL ; *AST ALT &gt; =5 time upper limit normal subject document liver metastasis ( &gt; 2.5 time upper limit normal subject without evidence liver metastasis ) ; *Serum creatinine &gt; 2.0 mg/dL ; *Hemoglobin &lt; 9 gm/dL ( may transfuse maintain exceed level ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Metastatic</keyword>
</DOC>